Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
D000328:Adult; D000368:Aged; D001806:Blood Urea Nitrogen; D003128:Coma / Q000139:chemically induced; D003681:Dehydration / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D006177:Gynecomastia / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D006973:Hypertension / Q000188:drug therapy; D007010:Hyponatremia / Q000139:chemically induced; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy; D011189:Potassium Chloride / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced; D013148:Spironolactone / Q000009:adverse effects* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D013148:Spironolactone; D011189:Potassium Chloride